Secretome

also known as Conditioned Medium · ADMSCS · CM-WJMSCs · MSC-Derived Secretome

Developed for: osteoarthritis, knee · acne · acute respiratory distress syndrome · androgenetic alopecia · cerebral palsy · chronic ulcer of skin · cirrhosis of liver · dementia
+6 more
· epilepsy · graft versus host disease · ischemic stroke · keloid · lupus erythematosus · retinitis pigmentosa
Investigated by: PT. Prodia Stem Cell Indonesia · Tarumanagara University · Baermed · B-Crobes Laboratory (M) Sdn Bhd · COR clinic of Regenerative Medicine · Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore.
+12 more
· LPPT TARUMANAGARA · Liver Clinic Prof Ali Sulaiman · Padjadjaran University · Pelni Hospital · RS Prof. Dr. I.G.N.G Ngoerah · Rumah Sakit Pusat Angkatan Darat Gatot Soebroto · SCARM Institute, Tabriz, Iran · Tabriz University of Medical Sciences · Universitas Sebelas Maret · University of the Punjab · Yohanes Firmansyah, dr, MH, MM · panti werda hana

Trials 15 · a red edge is where a trial was stopped

today NCT07429253 · Ph 1/2 NCT07157891 · Ph 0 NCT06925386 · Ph 2 NCT06638970 · Ph 1 NCT06629909 · Ph 1 NCT06632470 · Ph 1 NCT07439848 · Ph 1/2 NCT06469411 · Ph 3 NCT05921058 · Ph 1/2 NCT05008588 · Ph 1/2 NCT04314687 · Ph 1/2 NCT06217627 · Ph 1 NCT04326959 · Ph 1/2 NCT04314661 · Ph 1/2 NCT05777213 · Ph 1

2019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07157891	Dec 2025 → Dec 2027 expected	osteoarthritis, knee	University of the Punjab	Not yet recruiting	No outcome recorded
Phase 15 trials
Phase 1	NCT06638970	Dec 2024 → Oct 2025 overdue	epilepsy	Baermed	Not yet recruiting	No outcome recorded
Phase 1	NCT06629909	Dec 2024 → Oct 2025 overdue	cirrhosis of liver	Baermed	Not yet recruiting	No outcome recorded
Phase 1	NCT06632470	Oct 2024 → May 2025 overdue	dementia	Baermed	Not yet recruiting	No outcome recorded
Phase 1	NCT06217627	Mar 2021 → Jan 2023	—	COR clinic of Regenerative Medicine	Completed	No outcome recorded
Phase 1	NCT05777213	Jan 2019 → Jan 2022	chronic ulcer of skin, leprosy	Yohanes Firmansyah, dr, MH, MM	Completed	No outcome recorded
Phase 1/27 trials
Phase 1/2	NCT07429253	Jan → Jun 2026 overdue	androgenetic alopecia	PT. Prodia Stem Cell Indonesia	Recruiting	No outcome recorded
Phase 1/2	NCT07439848	Dec 2023 → Dec 2026 expected	acute respiratory distress syndrome	PT. Prodia Stem Cell Indonesia	Recruiting	No outcome recorded
Phase 1/2	NCT05921058	Aug → Dec 2022	lupus erythematosus	Universitas Sebelas Maret	Completed	No outcome recorded
Phase 1/2	NCT05008588	May 2022 → Mar 2026 overdue	ischemic stroke	PT. Prodia Stem Cell Indonesia	Active not recruiting	No outcome recorded
Phase 1/2	NCT04314687	Oct 2021 → Jul 2026 overdue	cerebral palsy	PT. Prodia Stem Cell Indonesia	Active not recruiting	No outcome recorded
Phase 1/2	NCT04326959	Sep 2020	keloid	PT. Prodia Stem Cell Indonesia	Unknown	No outcome recorded
Phase 1/2	NCT04314661	Aug 2020 → Jul 2024	osteoarthritis, knee	PT. Prodia Stem Cell Indonesia	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT06925386	May → Dec 2025 overdue	acne	Padjadjaran University	Not yet recruiting	No outcome recorded
Phase 31 trial
Phase 3	NCT06469411	Jan → Jun 2023	graft versus host disease	Tabriz University of Medical Sciences	Completed	No outcome recorded

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT04315025 Comparator	Oct 2018 → Jun 2019	retinitis pigmentosa	PT. Prodia Stem Cell Indonesia	Completed	No outcome recorded
Phase not applicable1 trial
—	NCT07137130 Background	Feb → May 2026 overdue	hyperpigmentation of the skin	Indonesia University	Not yet recruiting	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

Field	Value	Cited text
Known as	Secretome	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06469411 ↗ 11 NCT04314661 ↗ NCT06629909 ↗ NCT07439848 ↗ NCT07137130 ↗ NCT06632470 ↗ NCT06638970 ↗ NCT05921058 ↗ NCT06925386 ↗ NCT05777213 ↗ NCT07429253 ↗ NCT06217627 ↗
Known as	ADMSCS	“Development Of Adipose-Derived Mesenchymal Stem Cells Secretome (ADMSCS) Based Products From Stem Cell Conditioned Medium For Melasma Therapy” NCT07137130 ↗
Known as	CM-WJMSCs	“The interventions given in this study were Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs) as much as 0.1cc / 1cm intracutaneously with a flexpen...” NCT05777213 ↗
Known as	Conditioned Medium	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05008588 ↗ 3 NCT04314687 ↗ NCT04326959 ↗ NCT04315025 ↗
Known as	MSC-Derived Secretome	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157891 ↗
Modality	Other / unclassified	“Conditioned Medium Wharton's Jelly-derived mesenchymal stem cells (CM-WJMSCs)” NCT05777213 ↗
Route	Other	“via Intra-articular” NCT04314661 ↗